Injection, burosumab-twza 1m
Products billed under this code include Crysvita.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Crysvita.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Crysvita | Kyowa Kirin, Inc. | 42747-0102-01 | 10 | $5,168.50 |
| Crysvita | Kyowa Kirin, Inc. | 42747-0203-01 | 20 | $10,337.00 |
| Crysvita | Kyowa Kirin, Inc. | 42747-0304-01 | 30 | $15,505.50 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $516.85 | +$3.479 | 1 MG | Injection, burosumab-twza 1m | v1, posted September 17, 2026 |
| 3Q26 | $513.371 | +$14.655 | 1 MG | Injection, burosumab-twza 1m | v1, posted September 15, 2026 |
| 2Q26 | $498.716 | +$0.699 | 1 MG | Injection, burosumab-twza 1m | v1, posted September 15, 2026 |
| 1Q26 | $498.017 | +$13.879 | 1 MG | Injection, burosumab-twza 1m | v1, posted September 15, 2026 |
| 4Q25 | $484.138 | +$2.57 | 1 MG | Injection, burosumab-twza 1m | v1, posted September 8, 2026 |
| 3Q25 | $481.568 | +$11.826 | 1 MG | Injection, burosumab-twza 1m | v1, posted March 10, 2026 |
| 2Q25 | $469.742 | +$0.016 | 1 MG | Injection, burosumab-twza 1m | v1, posted March 10, 2026 |
| 1Q25 | $469.726 | +$0.15 | 1 MG | Injection, burosumab-twza 1m | v1, posted December 19, 2025 |
| 4Q24 | $469.576 | +$4.836 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 11, 2025 |
| 3Q24 | $464.74 | +$16.877 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 11, 2025 |
| 2Q24 | $447.863 | +$4.36 | 1 MG | Injection, burosumab-twza 1m | v1, posted March 11, 2025 |
| 1Q24 | $443.503 | +$9.981 | 1 MG | Injection, burosumab-twza 1m | v1, posted December 19, 2024 |
| 4Q23 | $433.522 | +$7.45 | 1 MG | Injection, burosumab-twza 1m | v1, posted October 10, 2024 |
| 3Q23 | $426.072 | +$11.359 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 5, 2024 |
| 2Q23 | $414.713 | +$3.697 | 1 MG | Injection, burosumab-twza 1m | v1, posted February 23, 2024 |
| 1Q23 | $411.016 | +$8.588 | 1 MG | Injection, burosumab-twza 1m | v1, posted December 6, 2023 |
| 4Q22 | $402.428 | +$0.93 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 22, 2023 |
| 3Q22 | $401.498 | +$21.398 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 9, 2023 |
| 2Q22 | $380.10 | −$0.046 | 1 MG | Injection, burosumab-twza 1m | v1, posted December 14, 2022 |
| 1Q22 | $380.146 | +$11.038 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 8, 2022 |
| 4Q21 | $369.108 | +$0.078 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 2, 2022 |
| 3Q21 | $369.03 | +$7.095 | 1 MG | Injection, burosumab-twza 1m | v1, posted June 2, 2022 |
| 2Q21 | $361.935 | −$0.019 | 1 MG | Injection, burosumab-twza 1m | v1, posted March 1, 2022 |
| 1Q21 | $361.954 | – | 1 MG | Injection, burosumab-twza 1m | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.